Welcome to our dedicated page for VSEE HEALTH SEC filings (Ticker: VSEEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VSEE HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VSEE HEALTH's regulatory disclosures and financial reporting.
VSee Health, Inc. entered into two unsecured convertible note financings with institutional investors, raising aggregate principal of $280,000 from ClearThink and $295,550 from Vanquish, each including an original issue discount. The ClearThink note carries a one-time 10% interest charge, matures on June 22, 2027, and becomes convertible after 180 days at 85% of the lowest closing price over the prior ten trading days, with a $0.01 floor and a 4.99% beneficial ownership cap.
The Vanquish note carries a one-time 12% interest charge, matures on April 15, 2027, and is convertible after the later of 180 days from issuance or an Event of Default at 75% of the lowest closing bid price over the prior ten trading days, also subject to a 4.99% beneficial ownership cap. Both notes were issued in private placements exempt from registration under Section 4(a)(2) and/or Regulation D.
VSee Health, Inc. reports that noteholder ADI Funding, LLC has delivered a notice asserting an Event of Default under an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, including an original issue discount of $21,739.13.
The holder’s notice alleges the company failed to meet several obligations tied to a June 8, 2026 securities purchase agreement, including filing a resale registration statement and issuing transfer agent instructions by June 11, 2026. Under the note, VSee Health has ten Trading Days from the Event of Default to cure. If not cured, the holder may accelerate the debt, enforce collateral rights, seek payment of all amounts due including any Mandatory Default Amount, and recover attorneys’ fees and costs. The company is evaluating potential resolution alternatives, including a consensual resolution, while expressly preserving all of its rights, remedies and defenses.
VSee Health, Inc. entered into a high-interest note financing with an institutional investor. The company issued an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, which includes an original issue discount of $21,739.13. The note bears interest at 18% per annum and matures on December 8, 2026.
The company may prepay all or part of the note at 100% of the amount redeemed plus a 10% prepayment fee. If VSee receives proceeds from an equity line of credit with the same holder, it must repay the entire outstanding balance within two business days. The note is secured by certain company assets under a related security agreement.
VSee Health, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., giving the company the right to sell up to $10 million of common stock over time. The arrangement runs until June 2, 2029, unless the full commitment is used or it is terminated earlier.
Shares sold under each Advance will be priced at 97% of the lowest daily VWAP over a three-day pricing period. VSee will issue 532,481 commitment shares and pay a $25,000 structuring fee from the first Advance. Issuances are capped at 9,715,140 shares, about 19.99% of pre-agreement outstanding shares, and the investor’s beneficial ownership is limited to 4.99%.
VSee Health, Inc. agreed to sell all of the equity of its wholly owned subsidiary VSee Lab, Inc. to co-Chief Executive Officer and Chairman Milton Chen, effective May 31, 2026. In return, Chen will transfer to the company all 2,870,069 shares of VSee Health common stock he owns, which are treated as a stock repurchase.
Under the agreement, Chen is solely responsible for indebtedness and other liabilities of VSee Lab not paid at closing, while VSee Health remains responsible for liabilities tied to periods on or before the closing date, including most taxes. Concurrent with closing, Chen resigned as co-Chief Executive Officer and chairman; co-CEO Dr. Imoigele Aisiku became sole Chief Executive Officer and chairman.
Unaudited pro forma financials show how results would look without VSee Lab and its subsidiary. For 2025, revenue would decline from $14,618,184 to $7,302,954, while net loss would narrow from $14,712,850 to $9,972,749. For the quarter ended March 31, 2026, revenue would fall from $3,160,185 to $1,879,293 and net loss would narrow from $2,600,262 to $1,264,882.
VSee Health, Inc. director and Co-Chief Executive Officer Milton Chen reported an internal restructuring transaction. On May 31, 2026, he transferred 2,870,069 shares of Common Stock to VSee Health, Inc. as consideration under a Stock Purchase Agreement related to his purchase of all equity securities of VSee Lab, Inc. from the company. Following this transaction, his directly held VSee common stock position was reported as 0 shares.
VSee Health, Inc. reported first‑quarter 2026 revenue of $3.16 million, compared with $3.32 million in the prior‑year quarter. Gross margin was $1.20 million while operating expenses rose to $4.17 million, leading to a net operating loss of $2.97 million.
Net loss narrowed to $2.60 million versus $3.96 million a year earlier, helped by a $367,809 gain on extinguishment of financial liabilities and a $143,040 gain from changes in fair value of financial instruments. Basic and diluted loss per share was $0.05 on a weighted average of 47.9 million shares.
Cash declined to $1.35 million from $5.27 million at December 31, 2025, with operating activities using $2.45 million of cash in the quarter. The company ended the period with total assets of $19.0 million, liabilities of $12.7 million, and stockholders’ equity of $6.32 million, alongside an accumulated deficit of $85.0 million. Management states that recurring losses and liquidity conditions raise substantial doubt about VSee Health’s ability to continue as a going concern.
VSee Health, Inc. Schedule 13G/A reports that Armistice Capital, LLC and Steven Boyd together beneficially own 4,861,392 shares, representing 9.99% of the outstanding common stock. The filing states Armistice Capital shares voting and dispositive power over those shares through its role as investment manager of Armistice Capital Master Fund Ltd.
The statement explains the Master Fund is the direct holder and that the Master Fund "specifically disclaims beneficial ownership" by reason of its inability to vote or dispose under its Investment Management Agreement. The amendment is signed by Steven Boyd on 05/15/2026.
VSee Health, Inc. files its annual report describing a telehealth software platform and high-acuity critical care services alongside significant losses and going‑concern risks. The company reported operating losses of $9,582,893 in 2025 and $62,150,845 in 2024, with an accumulated deficit of $82,416,723 as of December 31, 2025. Its auditor highlighted substantial doubt about VSee’s ability to continue as a going concern due to ongoing losses and negative operating cash flows.
VSee delivers configurable, no‑code and low‑code telehealth tools through VSee Lab and tele‑ICU and specialty physician services through iDoc, targeting hospital systems, ICUs, correctional facilities and other high‑acuity settings. Competition is intense from large telehealth vendors, EMR‑embedded tools and in‑house solutions. The company faces heavy regulatory exposure, including HIPAA, state privacy rules, anti‑kickback and self‑referral laws, False Claims Act risk and evolving Medicare/Medicaid telehealth reimbursement. VSee also depends heavily on a small number of major customers and approximately 93 board‑certified physicians within a 209‑person workforce.
Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.